SCHEDULE: Tang Capital Boosts Compass Therapeutics Stake to 9.99%

Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in Compass Therapeutics, Inc., comprising common stock and exercisable warrants.

Summary

• Tang Capital Management, LLC and its affiliates (Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.) collectively beneficially own 17,176,510 shares of Compass Therapeutics, Inc. common stock.
• This represents 9.99% of the Issuer's outstanding Common Stock.
• The ownership consists of 16,811,963 shares of Common Stock and 364,547 shares currently issuable upon exercise of Warrants.
• The percentage is calculated based on 171,937,045 shares outstanding, which includes 171,572,498 shares of Common Stock outstanding as of August 11, 2025, and the 364,547 shares currently issuable upon exercise of Warrants.
• All reporting persons share voting and dispositive power over these shares.
• Certain warrants held by Tang Capital Partners, LP and Tang Capital Partners International, LP are subject to ownership limitations, restricting their immediate exercise to maintain beneficial ownership below 9.99% (or 19.99% with 61 days notice).

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued beneficial ownership stake by a prominent investment firm, which generally signals confidence in the company. The 9.99% stake is substantial, suggesting a long-term interest, although it's an amendment, not a new position.

Positives

• A significant beneficial ownership stake of 9.99% by Tang Capital Management and its affiliates indicates a strong conviction in Compass Therapeutics, Inc.
• The continued holding and disclosure of this substantial position by a prominent investment firm can be viewed as a positive signal to the market regarding the company's long-term prospects.

Risks

• The beneficial ownership percentage is capped at 9.99% due to warrant exercise limitations, which could restrict Tang Capital's ability to immediately increase its stake through warrant conversion without prior notice to the Issuer and a 61-day waiting period for certain increases.

Industry Context

The disclosure of a significant stake by an investment firm like Tang Capital Management in a biotechnology company such as Compass Therapeutics, Inc. is a common occurrence in the industry. Such filings provide transparency into institutional investor positions, which can sometimes influence market perception and trading activity, especially for companies in the often volatile biotech sector.

Related Party Transactions

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. are identified as a group sharing voting and dispositive power over the reported shares. Tang Capital Management, LLC is the general partner of TCP and TCPI, and Kevin Tang is the manager of TCM and CEO of TCP III and TCP IV, indicating an interconnected group structure.

Stakeholder Impact

• Shareholders may view the significant stake held by Tang Capital Management and its affiliates as a positive indicator of institutional confidence in Compass Therapeutics, Inc.
• The presence of a large institutional investor could potentially influence future strategic decisions or corporate governance, although the filing certifies no intent to change or influence control.

Next Steps

• Tang Capital Partners, LP and Tang Capital Partners International, LP may increase their beneficial ownership percentage up to 19.99% by providing written notice to the Issuer, with such increase becoming effective 61 days after notice.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Tang Capital Management and its affiliates, indicating a substantial 9.99% stake in Compass Therapeutics, Inc. While it doesn't provide new operational or financial performance data, the continued presence of a significant institutional investor suggests a degree of confidence in the company's long-term prospects. For an investor, this information supports a 'hold' position, as it confirms institutional backing without offering new catalysts for a 'buy' or 'sell' decision based solely on this filing. The ownership limitation on warrant exercise also suggests a stable, rather than aggressive, accumulation strategy at this time.

Keywords

Compass Therapeutics, Tang Capital Management, CTIC, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, biotech, pharmaceutical